Nama's AI scorecard currently rates Bio-Rad Laboratories Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BIO's P/E ratio?

Bio-Rad Laboratories trades at a trailing price-to-earnings ratio of 39.5.

When does BIO report earnings?

Bio-Rad Laboratories's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $3.02.

What is the BIO price target?

The median analyst price target from 3 analysts is $335.00, with a range of $280.00 – $390.00.

Is BIO Shariah compliant?

Nama's AAOIFI-style screen reads Bio-Rad Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Bio-Rad Laboratories (BIO)

Healthcare · Medical Devices · NYSE

Bio-Rad Laboratories (BIO) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $10.26B, a trailing price-to-earnings ratio of 39.5 and a free-cash-flow yield of 3.6%. Over the most recent reported fiscal year, revenue grew 0.7% and free cash flow per share grew 45.5%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +20.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-51.4%

How far the last close sits under the highest price of the past five years.

Market cap	$10.26B
Trailing P/E	39.5
Price / book	1.4
Price / sales	3.9
FCF yield	3.6%
Dividend yield	—
Gross margin	51.9%
Operating margin	8.7%
Net margin	8.6%
Revenue growth (YoY)	+0.7%
Revenue growth (3-yr annual)	-2.7%
EPS growth (YoY)	-3.8%
FCF/share growth (YoY)	+45.5%
Beta	1.1
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

BIO earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $3.02). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$2.65	$2.23	+18.8%	$656.40M
Q2 2026	Aug 4, 2026	$2.62	$1.75	+49.7%	$651.00M
Q1 2026	Apr 30, 2026	$1.89	$1.99	-5.0%	$592.10M
Q4 2025	Feb 12, 2026	$2.51	$2.70	-7.0%	$693.20M

BIO analyst price target

Median target $335.00 from 3 analysts, ranging $280.00 – $390.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live BIO data on Nama Insights →

Recent Congressional trades

Bio-Rad Laboratories trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lois Frankel	House	Sell	$1,001 - $15,000	Oct 10, 2023
Thomas R Tillis	Senate	Sell	$1,001 - $15,000	—

BIO FAQ

Is BIO a buy?: Nama's AI scorecard currently rates Bio-Rad Laboratories Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BIO's P/E ratio?: Bio-Rad Laboratories trades at a trailing price-to-earnings ratio of 39.5.
When does BIO report earnings?: Bio-Rad Laboratories's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $3.02.
What is the BIO price target?: The median analyst price target from 3 analysts is $335.00, with a range of $280.00 – $390.00.
Is BIO Shariah compliant?: Nama's AAOIFI-style screen reads Bio-Rad Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.